SRZN insider trading
HealthcareSurrozen, Inc./DE — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Surrozen, Inc./DE
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Company website: www.surrozen.com
SRZN insider activity at a glance
FilingIQ has scored 153 insider transactions for SRZN since Aug 11, 2021. The most recent filing in our index is dated May 13, 2026.
Across the full history, 69 open-market purchases
and 11 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SRZN insider trades is 51.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SRZN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading SRZN
Frequently asked
- How many insider trades does FilingIQ track for SRZN?
- FilingIQ tracks 153 Form 4 insider transactions for SRZN (Surrozen, Inc./DE), covering filings from Aug 11, 2021 onwards. 32 of those were filed in the last 90 days.
- Are SRZN insiders net buyers or net sellers?
- Across the full Form 4 history for SRZN, 69 transactions (45%) were open-market purchases and 11 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SRZN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is SRZN in?
- Surrozen, Inc./DE (SRZN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $208.20M.
Methodology & sources
Every SRZN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.